Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only reported activity is an increase in ADS holdings for specific individuals following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details the reinvestment of dividends paid on July 9, 2015, at a price of $41.80 per ADS.
Important Facts for Investors
- Transactions involve Dr. M M Slaoui (288.361 ADSs) and Mr. D E Troy (387.958 ADSs).
- The transactions resulted from the reinvestment of dividends paid on July 9, 2015.
- The transaction price was $41.80 per ADS.
- This filing does not contain financial results or operational updates.